PTK-7 Antibody-Drug Conjugates for Targeted Bystander Activity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for Protein Tyrosine Kinase 7 (PTK-7) antibody-drug conjugates (ADCs) that offer improved therapeutic index, tolerability, efficacy, bystander activity against PTK-7-low tumors, enhanced stability, and reduced immunogenicity, while maintaining specificity and stability for effective cancer treatment.

Innovation Solution

Development of PTK-7 ADCs with specific antibody sequences and modified IgG1 Fc regions, conjugated to camptothecin analogs via cleavable linkers, designed for targeted delivery and intracellular activation, with controlled drug-to-antibody ratios and engineered cysteine residues for enhanced stability and reduced effector function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PTK-7 ADCs are designed with high potency against tumor cells, then anti-tumor activity is improved, but toxicity to healthy cells increases

Engineering Contradiction:

Improveanti-tumor activityVSAvoidtoxicity to healthy cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses a targeted antibody (PTK-7 antibody) as an intermediary to deliver the cytotoxic payload specifically to tumor cells expressing PTK-7. The antibody acts as a mediator that binds to the tumor cell surface receptor, enabling selective delivery of the toxic agent only to target cells while sparing healthy cells, thus resolving the contradiction between potency and toxicity

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The ADC design implements local quality by concentrating the cytotoxic effect only at the tumor cell location through antibody-mediated targeting. The payload is activated locally within the tumor cell after internalization, ensuring that the harmful effect is localized to PTK-7 expressing cells while maintaining system-wide safety

Inventive Principle:

Principle #3Local quality

2Ease of operation

If ADCs are designed with labile payloads for intracellular delivery, then intracellular delivery is improved, but physical and chemical stability deteriorates

Engineering Contradiction:

Improveintracellular deliveryVSAvoidphysical and chemical stability

Core Design Contradiction:

Ease of operationVSStability of the object's composition

Solution Approach 1:

The patent employs a stable antibody component that maintains structural integrity during circulation, while the payload is designed with conditional lability - stable in circulation but designed to be released intracellularly through specific triggers (e.g., endosomal pH, enzymatic cleavage). The antibody is pre-engineered with cysteine residues at specific positions (e.g., H236, H239, L234, L235) that serve as predetermined attachment sites for the payload, enabling controlled intracellular activation without compromising overall stability

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The payload stability is made conditional based on the environmental parameters - the linker-payload construct remains stable at physiological pH and temperature during circulation but undergoes parameter change (cleavage) upon encountering specific intracellular conditions (low pH in endosomes/lysosomes or presence of specific enzymes), thereby achieving both stability during transport and lability for intracellular delivery

Inventive Principle:

Principle #35Parameter changes

3Reliability

If ADCs are designed with high therapeutic index, then efficacy is improved, but tolerability deteriorates

Engineering Contradiction:

ImproveefficacyVSAvoidtolerability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The PTK-7 antibody serves as a selective intermediary that bridges the cytotoxic payload and PTK-7 expressing tumor cells. This targeted approach allows high doses of potent payloads to be administered while the antibody mediator ensures selective delivery only to cancer cells, thereby achieving high efficacy without compromising patient tolerability due to reduced off-target effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The therapeutic window is optimized by controlling the drug-to-antibody ratio (DAR) and using cleavable linkers that remain stable in circulation but release payload intracellularly. The payload is designed with parameters that allow it to be stable at circulation concentrations but become activated only after internalization, creating a parameter-based switch that improves both efficacy and tolerability

Inventive Principle:

Principle #35Parameter changes

4Reliability

If ADCs are designed with enhanced bystander activity, then activity against PTK-7-low tumors is improved, but specificity to PTK-7 targets deteriorates

Engineering Contradiction:

Improvebystander activityVSAvoidspecificity to PTK-7 targets

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent employs a segmented approach where the antibody component maintains strict PTK-7 binding specificity for targeted delivery, while the payload component is designed to release its cytotoxic effect beyond the targeted cell through bystander mechanisms (e.g., payload release into extracellular space or uptake by neighboring cells). This segmentation allows the antibody to maintain targeting precision while the payload provides extended bystander activity against PTK-7-low or heterogeneous tumor populations

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20250332277A1Protein tyrosine kinase 7 antibodies and antibody-drug conjugates

Publication Date: 2025.10.30 ELI LILLY & CO

AI summary

The present disclosure provides PTK-7 antibody drug conjugates and pharmaceutical compositions thereof, and methods of using for the treatment of cancer.